10d
Zacks Investment Research on MSNNovo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...
9d
GlobalData on MSNNovo Nordisk cuts Wegovy price through new direct-to-patient online pharmacyThe Danish drugmaker has launched a new online pharmacy called NovoCare Pharmacy to cut out the middlemen it so frequently ...
Novo Nordisk's obesity drug CagriSema failed to outperform Eli Lilly's Mounjaro in the latest trial, causing a dip in Novo's ...
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...
Novo Nordisk NVO announced that it is launching ... Zacks Investment Research Image Source: Zacks Investment Research The discounted prices come on the heels of the FDA’s announcement in late ...
Miach Orthopaedics announced today that the FDA cleared an expanded indication for the company's Bear implant for ACL tears.
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking The ...
12d
GlobalData on MSNNovo Holdings and TA Associates back BiocompositesDanish asset manager Novo Holdings, which is owned by Novo Nordisk Foundation (NNF), the majority voting shareholder of ...
Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results